Pancreatic Cancer Research

ResearcherThe University of Texas at San Antonio Health Science CenterActive in the last 2 years

William C. Small

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1623-9863; OpenAlex author ID A5025234993, A5112191048. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 0, last author 2)
Trials
1
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 2 papers · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 11

  1. ACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update. Co-author DOI 10.1016/j.jacr.2025.08.037↗
  2. Cytosolic transport of citrate protects nutrient-austere pancreatic cancer from ferroptosis Co-author DOI 10.1101/2025.01.15.633097↗
  3. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  4. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Revie… Co-author DOI 10.1097/coc.0000000000001076↗
  5. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG … Co-author DOI 10.1002/cncr.31058↗
  6. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000370↗
  7. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unres… Last author DOI 10.1007/s12029-016-9821-9↗
  8. Stereotactic body radiotherapy for pancreatic cancer: recent progress and future directions. Co-author DOI 10.1586/14737140.2016.1168698↗
  9. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. Co-author DOI 10.1007/s11605-012-2064-6↗
  10. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized panc… Co-author DOI 10.1016/j.ijrobp.2010.02.030↗
  11. Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT. Last author DOI 10.1016/j.ijrobp.2010.05.060↗

Trials 1

  1. Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer Study chair NCT00460174↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elena Gabriela Chiorean · 2 shared papers, 2013–2025 · strength 0.24
  2. Rachit Kumar · 2 shared papers, 2017–2024 · strength 0.24
  3. Salma K. Jabbour · 2 shared papers, 2017–2024 · strength 0.24
  4. Percy P. Lee · 2 shared papers, 2017–2024 · strength 0.24
  5. Suzanne M. Russo · 2 shared papers, 2016–2024 · strength 0.23
  6. Ali Vaziri Gohar · 1 shared paper, 2025 · strength 0.23
  7. Adam Kneebone · 1 shared paper, 2025 · strength 0.23
  8. Alice Fung · 1 shared paper, 2025 · strength 0.21
  9. David H. Kim · 1 shared paper, 2025 · strength 0.21
  10. Atif Zaheer · 1 shared paper, 2025 · strength 0.21
  11. Aslam M. Ejaz · 1 shared paper, 2025 · strength 0.21
  12. Christopher Leigh Hallemeier · 1 shared paper, 2024 · strength 0.18
  13. Leila T. Tchelebi · 1 shared paper, 2024 · strength 0.18
  14. Krishan R. Jethwa · 1 shared paper, 2024 · strength 0.18
  15. Jordan D. Berlin · 1 shared paper, 2024 · strength 0.18
  16. Mary F. Mulcahy · 4 shared papers, 2011–2016 · strength 0.15
  17. Joseph M. Herman · 2 shared papers, 2016–2017 · strength 0.11
  18. Chandan Guha · 1 shared paper, 2018 · strength 0.07
  19. William F. Regine · 1 shared paper, 2018 · strength 0.07
  20. Talia Golan · 1 shared paper, 2018 · strength 0.07
  21. Yaacov Richard Lawrence · 1 shared paper, 2018 · strength 0.07
  22. Adam Paul Dicker · 1 shared paper, 2018 · strength 0.07
  23. Christopher H. Crane · 1 shared paper, 2018 · strength 0.07
  24. Albert C. Koong · 1 shared paper, 2017 · strength 0.06
  25. Karyn A. Goodman · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.